ClinicalTrials.gov
public full text
Public Domain
Liposomal Bupivacaine in Total Knee Arthroplasty
Pain management after total knee arthroplasty is essential for optimized clinical outcomes and higher satisfaction. Exparel (Pacira Pharmaceuticals, Parsippany, New Jersey, USA) is a long-acting Bupivacaine extended release liposome compound that is injected peri-articularly or as regional block. The purpose of this study was to compare the analgesic efficacy of single administration of Exparel for local peri-articular infiltration versus adductor canal regional block.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures#867385
- Liposomal Bupivacaine for Post-operative Pain Control in Adolescent Bariatric Patients#880767
- A Study of Bupivacaine Liposome Injection in Local Analgesia of Pediatric Patients#829408
- Post Operative Pain Management Through Adductor Canal Block With Bupivacaine for ACL Reconstruction#993208
- Liposomal Bupivacaine in Total Knee Arthroplasty#1410742
Record · ID 1437455
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive